Опубликовать статью

Информационное партнерство

Инфоресурсы

Контакты

«

Vol. 22, Art. 4 (pp. 49-61)    |    2021       

»

Quality of life, symptom burden and serum malonic dialdehide concentration in multiple myeloma patients after autologous stem cell transplantation

Federal State Budget Institution Russian research institution of hematology and transfusiology of Federal Biomedical Agency. 191024, Russia, St. Petersburg
St. Petersburg State University, N.I. Pirogov Clinic of High Medical Technologies, 190103, St. Petersburg
3Multinational Center for Quality-of-Life Research, 191014, St. Petersburg

Brief summary

Background. Complications after autologous stem cell transplantation (ASCT) were associated with decrease of patients (pts) quality of life (QoL) index. Oxidative imbalance also may affect symptom burden. The aim of our study was to investigate possible association between symptom burden and oxidative stress activity in multiple myeloma (MM) pts during the early post-transplantation period. Materials and Methods. The retrospective analysis of 24 pts data (median age is 58 years) was performed. The MDASI and the SF-36 questionnaires were used for symptom and QoL assessment. Plasma antioxidant status was measured by detecting the level of serum malonic dialdehide (MDA). MDA level was detected by the colorimetric method. Statistical analysis was performed by Microsoft Exel 2013 and StatSoft Statistica 10. Results. In early post-transplantational period QoL index decreased significantly at Day+7 after ASCT (p<0,0001). MDA level was higher than normal before ASCT in all pts: 16.7 +/- 4.2 mcmol/l (normal level is <1.2x104 mcmol/l). Nine pts (37.5%) exhibited MDA level decrease - mean value change after ASCT was 5.36 mcmol/l At the same time in this group were observed significant changes in symptom severity. Correlation between changes in MDA level and symptom intensity was observed (rs=0.76; p<0.01). There were no hematological and clinical differences between pts with and without MDA level decrease. Conclusion. Detected association between symptom severity decrease and MDA level decrease may be used as an important rationale for clinical application of supportive therapy with anti-oxidant activity in post-transplantation period.


Key words

multiple myeloma, autologous stem cell transplantation, quality of life, symptom burden, malonic dialdehide.

Reference list

1. Bessmelcev S.S. Mnojestvennaya mieloma: rykovodstvo dlya vrachei / Bessmelcev S.S., Abdylkadirov K.M.// M.: MK - 2016.


2. Mendeleeva L.P. Nacionalnie klinicheskie rekomendacii po diagnostike i lecheniu mnojestvennoi mielomi/ Mendeleeva L.P., Votyakova O.M., Pokrovskaya O.S. i dr. // Gematologiya i transfyziologiya - 2016, 61(1, Pril.2) - S 1-24.


3. Kvam A.K., Waage A. Health-related quality of life in patients with multiple myeloma--does it matter // Haematologica. - 2015 - Vol. 100(6), P. 704-705 doi: 10.3324/haematol.2015.127860.


4. Royle K.L., Gregory W.M., Cairns D.A. et al. Quality of life during and following sequential treatment of previously untreated patients with multiple myeloma: findings of the Medical Research Council Myeloma IX randomised study // Br J Haematol. - 2018 - Vol. 182(6), P. 816-829 doi https://doi.org/10.1111/bjh.15459.


5. Arytunyan A.V. Metodi ocenki svobodnoradikalnogo okisleniya i antioksidantnoi sistemi organizma / Arytunyan A.V., Dybinina E.E., Zibina N.N. SPb - 2000.


6. Sloot S., Boland J., Snowden J.A. et al. Side effects of analgesia may significantly reduce quality of life in symptomatic multiple myeloma: a cross-sectional prevalence study // Support Care Cancer. - 2015 - Vol.23(3), P. 671-678 doi https://doi.org/10.1007/s00520-014-2358-1.


7. Balderas-Pena L.M., Miranda-Ruvalcaba C., Robles-Espinoza A.I. et al. Health-related quality of life and satisfaction with health care: relation to clinical stage in Mexican patients with multiple myeloma // Cancer Control. - 2019 - Vol. 26(1) - P. 1-8 https://doi.org/10.1177/1073274819831281.


8. Osborne T.R., Ramsenthaler C., de Wolf-Linder S. et al. Understanding what matters most to people with multiple myeloma: a qualitative study of views on quality of life// BMC Cancer.- 2014 - Vol. 14 P. 496 doi https://doi.org/10.1186/1471-2407-14-496.


9. Jordan K., Proskorovsky I., Lewis P. et al. Effect of general symptom level, specific adverse events, treatment patterns, and patient characteristics on health-related quality of life in patients with multiple myeloma: results of a European, multicenter cohort study. Support Care Cancer. - 2014 - Vol. 22(2) P. 417-426 doi https://doi.org/10.1007/s00520-013-1991-4.


10. Abonour R., Wagner L., Durie B.G.M et al. Impact of post-transplantation maintenance therapy on health-related quality of life in patients with multiple myeloma: data from the Connect? MM Registry// Ann Hematol. - 2018 - Vol.97(12) P. 2425-2436 doi https://doi.org/10.1007/s00277-018-3446-y.


11. Dimopoulos M.A., Palumbo A., Hajek R. et al. Factors that influence health-related quality of life in newly diagnosed patients with multiple myeloma aged ≥ 65 years treated with melphalan, prednisone and lenalidomide followed by lenalidomide maintenance: results of a randomized trial// Leuk Lymphoma. - 2014 Vol. 55(7), P.1489-1497 doi https://doi.org/10.1007/s00277-018-3446-y.


12. Ludwig H., Moreau P., Dimopoulos M.A. et al. Health-related quality of life in the ENDEAVOR study: carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed/refractory multiple myeloma// Blood Cancer J. - 2019 Vol. 9(3), P.23 https://doi.org/10.1038/s41408-019-0181-0.


13. Despiegel N., Touboul C., Flinois A. et al. Health-related quality of life of patients with multiple myeloma treated in routine clinical practice in France// Clin Lymphoma Myeloma Leuk. - 2019 - Vol.19(1), e13-e28 doi https://doi.org/10.1016/j.clml.2018.08.019.


14. Wagner L.I., Robinson D. Jr., Weiss M. et al. Content development for the Functional Assessment of Cancer Therapy-Multiple Myeloma (FACT-MM): use of qualitative and quantitative methods for scale construction// J Pain Symptom Manage. - 2012 - Vol. 43(6), P.1094-1104 doi https://doi.org/10.1016/j.jpainsymman.2011.06.019.


15. Ramsenthaler C., Osborne T.R., Gao W. et al. The impact of disease-related symptoms and palliative care concerns on health-related quality of life in multiple myeloma: a multi-center study // BMC Cancer. - 2016, Vol.16, P.427 doi https://doi.org/10.1186/s12885-016-2410-2.


16. Jurczyszyn A., Czepko R., Banach M. et al. Percutaneous vertebroplasty for pathological vertebral compression fractures secondary to multiple myeloma - medium-term and long-term assessment of pain relief and quality of life. Adv Clin Exp Med. 2015;24(4):651-656.


17. Pereira N.F., Silva P.V.R.D., Fukuoka C.Y. et al. Measurement of oral health quality of life among patients who underwent haematopoietic stem-cell transplantation.// Braz Oral Res. - 2018, Vol.32, e78 doi https://doi.org/10.17219/acem/38556.


18. Boland E., Eiser C., Ezaydi Y. et al. Living with advanced but stable multiple myeloma: a study of the symptom burden and cumulative effects of disease and intensive (hematopoietic stem cell transplant-based) treatment on health-related quality of life. // J Pain Symptom Manage. - 2013, Vol. 46(5), P.671-680 doi https://doi.org/10.1016/j.jpainsymman.2012.11.003.